Core Viewpoint - China Resources Double Crane (600062.SH) announced that its wholly-owned subsidiary, Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd. (referred to as "Shanghai Changfu"), has received the approval notice for the supplementary application of peritoneal dialysis solution (lactate-G1.5%) and peritoneal dialysis solution (lactate-G2.5%) from the National Medical Products Administration (NMPA) [1] Group 1 - The peritoneal dialysis solution (lactate) is primarily used for patients with acute and chronic renal failure who require continuous non-bedside peritoneal dialysis treatment due to ineffective non-dialysis therapy [1] - The approval of the supplementary application for the peritoneal dialysis solution (lactate) represents an enhancement of the product specifications, which is expected to benefit the future market sales and competitive potential of this product series [1]

Core Viewpoint - China Resources Double Crane (600062.SH) announced that its wholly-owned subsidiary, Shanghai Changzheng Fumin Jinsan Pharmaceutical Co., Ltd. (referred to as "Shanghai Changfu"), received the Drug Supplement Application Approval Notice from the National Medical Products Administration for peritoneal dialysis solutions (lactate-G1.5% and lactate-G2.5%) [1] Group 1 - The peritoneal dialysis solutions (lactate) are primarily suitable for patients with acute and chronic renal failure who require continuous non-bedside peritoneal dialysis treatment due to ineffective non-dialysis therapy [1] - The approval of the Drug Supplement Application is a further enhancement of the specifications for the peritoneal dialysis solutions (lactate), which will benefit the future market sales and competitive potential of this product series [1]